1. Scrip

Bristol Projects Opdivo Sales Will Grow Again In 2021

 
• By Mandy Jackson

With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.

SC1910_Lung Cancer_47781766_1200.jpg
Bristol expects first-line lung cancer to boost Opdivo sales starting in 2021. • Source: Shutterstock

Bristol-Myers Squibb Co. is optimistic that one-time PD-1 inhibitor market leader Opdivo (nivolumab) can return to growth in 2021 now that its Opdivo/Yervoy (ipilimumab) combination has delivered positive overall survival results in two first-line lung cancer studies, the company said during its 31 October third quarter earnings call.

But even with Opdivo sales flattening out due to competition from Merck & Co. Inc.’s anti-PD-1 drug Keytruda (pembrolizumab)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.